@angerlaugh8
Active 3 years, 8 months ago
This specific demo is registered with ClinicalTrials.gov, NCT00520806.
Findings 1161 individuals ended up aimlessly assigned to serelaxin (n=581) as well as placebo (n=580). Serelaxin improved upon the particular VAS AUC main dyspnoea endpoint (448 millimeters by l, 95% CI 120-775; p=0.Jason bourne) weighed against placebo, but didn’t […] View
There are no galleries available!

